Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Clinical trial NCT04688151 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04688151
Sponsor: National Health Research Institutes, Taiwan
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma (PCNSL)

Start date: 2021-02-22
Primary completion: 2025-12-31
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.